Suppr超能文献

在健康中国志愿者中,通过新型干粉吸入器给予丙酸倍氯米松/富马酸福莫特罗的药代动力学特征。

Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers.

机构信息

Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, China.

Chiesi Farmaceutici SpA, Parma, Italy.

出版信息

Pulm Pharmacol Ther. 2022 Jun;73-74:102129. doi: 10.1016/j.pupt.2022.102129. Epub 2022 May 4.

Abstract

INTRODUCTION

An extrafine formulation of the inhaled corticosteroid beclometasone dipropionate (BDP) plus the long-acting β-agonist formoterol fumarate (FF) has been available for years via a pressurised metered-dose inhaler for the management of asthma and chronic obstructive pulmonary disease. More recently, the same extrafine BDP/FF formulation has become available in a multidose dry-powder inhaler (DPI) called the NEXThaler. The pharmacokinetics (PK) of BDP/FF via this DPI have previously been evaluated in a Caucasian population. The current study aimed to evaluate the PK profile of BDP/FF via DPI in healthy Chinese volunteers. The results were then compared to previous Caucasian data.

METHODS

This open-label parallel group study randomised subjects to single-dose BDP/FF 200/12, 400/24, or 800/48 μg via DPI. Blood samples were taken up to 24 h post-dose for PK evaluation of BDP, beclometasone 17-monopropionate (B17MP, active metabolite of BDP) and formoterol. The primary objective of the study was to evaluate the PK of BDP/FF (BDP, B17MP and formoterol). The study is registered on the World Health Organization International Clinical Trials Registry Platform (ChiCTR1900021899).

RESULTS

Of 36 subjects randomised, all completed the study. Following inhalation of all three doses, plasma concentration of formoterol and BDP increased rapidly, with peak mean values at the first post-dose timepoint (5 min), then rapidly decreasing; B17MP reached peak concentration slightly later. Plasma exposure to formoterol, BDP and B17MP increased broadly in a dose-proportional manner to BDP/FF dose, with t values similar across the dose range. All BDP/FF doses were generally well tolerated.

CONCLUSIONS

Therapeutic and supra-therapeutic doses of BDP/FF administered via DPI resulted in approximately dose-proportional plasma exposure in healthy Chinese subjects, with PK profiles that were comparable to previous data from Caucasian subjects.

摘要

介绍

多年来,一种吸入性皮质类固醇倍氯米松二丙酸酯(BDP)与长效β-激动剂富马酸福莫特罗(FF)的超细配方一直通过压力计量吸入器用于管理哮喘和慢性阻塞性肺疾病。最近,同样的超细 BDP/FF 配方已在一种名为 NEXThaler 的多剂量干粉吸入器(DPI)中上市。此前,已经在白种人群中评估了通过该 DPI 给予 BDP/FF 的药代动力学(PK)。本研究旨在评估健康中国志愿者通过 DPI 给予 BDP/FF 的 PK 特征。然后将结果与以前的白种人数据进行比较。

方法

这项开放标签的平行组研究将受试者随机分为单剂量 DPI 给予 BDP/FF 200/12、400/24 或 800/48μg。在给药后长达 24 小时采集血样,用于 BDP、倍氯米松 17-丙酸酯(BDP 的活性代谢物 B17MP)和福莫特罗的 PK 评估。该研究的主要目的是评估 BDP/FF(BDP、B17MP 和福莫特罗)的 PK。该研究在世界卫生组织国际临床试验注册平台(ChiCTR1900021899)上注册。

结果

36 名随机受试者均完成了研究。所有三种剂量吸入后,福莫特罗和 BDP 的血浆浓度迅速升高,第一个给药后时间点(5 分钟)达到峰值均值,然后迅速下降;B17MP 达到峰值浓度稍晚。福莫特罗、BDP 和 B17MP 的血浆暴露量与 BDP/FF 剂量呈广泛的剂量比例关系增加,在剂量范围内 t 值相似。所有 BDP/FF 剂量总体上耐受性良好。

结论

在健康中国受试者中,通过 DPI 给予治疗和超治疗剂量的 BDP/FF 导致大约与 BDP/FF 剂量成比例的血浆暴露,PK 特征与白种人受试者的先前数据相当。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验